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Abstract
Diabetic retinopathy (DR) is one of the leading causes of preventable vision impairment 
and blindness in the working-age population worldwide. Numerous animal models 
have been developed for therapeutic drug screening and to further increase our under-
standing of the molecular and cellular pathological processes involved in DR. Following 
our discussion of mouse models in “Animal Models of Diabetic Retinopathy Part 1,” we 
describe the cellular, molecular, and morphological features of both rodent and non-
rodent models of DR and their respective advantages and limitations in this chapter. 
To date, no animal model can holistically reproduce the pathological progression of 
human DR; most only display early or advanced lesions of DR. However, a thorough 
understanding of genotypic and phenotypic expressions of existing models will facili-
tate researchers’ selection of the appropriate model to simulate their desired clinical 
scenarios.
Keywords: animals, blood glucose, blindness, diabetic complications, diabetes mellitus/
pathology/physiopathology, neovascularization, proliferative, retinal vessels
1. DR features of animal models
Among all the existing animal models of diabetic retinopathy (DR), mice and rats are most 
commonly used, possibly due to their small size, availability, genetic tractability, and relatively 
faster development of DR lesions as compared with larger animals. Tables 1–3 summarize the 
cellular, molecular, and morphological features of rat and nonrodent models of DR. Features 
of mouse models are detailed in the previous chapter (Animal Models of Diabetic Retinopathy 
Part 1).
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Rat model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in rat models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or induction of VEGF overexpression)
NPDR features PDR features Functional changes (ERG)
STZ 
injection
1 Within one wk • 1 wk+: reduced total retinal thickness [93]
• 2 wks+: increased retinal apoptosis [94]
  BRB breakdown [5, 93] (16 wks+ [6])
•  4 wks+: Müller cell gliosis [2, 3] (6 wks+ [4])  
(12 wks+ [5])
   Reduced NeuN-positive cells in GCL [3] 
(4 mo reduced number of cells in GCL [1])
  Reduced astrocyte number [5] (6 wks+ [2])
  Increased number of microglia [5] (4 mo+ [3])
  Reduced number of cells in ONL [93]
• 6 wks+: reduced astrocyte processes [2]
• 8 wks+: increased adherent leukocytes [7]
•  16 wks+: increased acellular capillaries [6] 
(8 mo+ [1])
  Decreased number of pericytes [6]
• 4 mo+: reduced NeuN-positive cells in INL [3]
• 8 mo+: pericyte ghosts [1]
• 12 mo+: capillary BM thickening [8]
•  2 wks+: decreased b-wave 
amplitude [4] (11 wks+ [9])  
(16 wks+ [6])
   Decreased OP amplitude [4]  
   (16 wks+ [6])
•  8 wks+: decreased OPs (not 
observed at 11 wks) [95]
•  11 wks+: increased a-wave 
implicit time [9]
   Decreased a-wave amplitude [9]  
   (10 wks+ [4])
   Delayed OPs [9]
Alloxan 
injection
1 • 6 wks+: BRB breakdown [96]
•  5 mo+: capillary occlusion with endothelial 
cell swelling [11]
• 8 mo+: retinal microvascular cell death [10]
• 9 mo+: IRMAs in lower capillary layer [11]
• 12 mo+: pericyte ghosts [12]
    Increased no. of acellular capillaries [12]  
(18 mo+ [10])
  Capillary BM thickening [12]
•  2 mo+: neovascularization in mid-
periphery region [11]
•  5 mo+: neovascularization in center 
and mid-periphery regions [11]
•  9 mo+: neovascularization in all 
regions [11]
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Rat model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in rat models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or induction of VEGF overexpression)
NPDR features PDR features Functional changes (ERG)
Galactose-
fed
/ / •  4 mo+: increased retinal microvascular cell 
apoptosis^ [10]
• 12 mo+: pericyte ghosts [12] (23 mo+)*^ [13]
   Increased no. of acellular capillaries [12]  
(23 mo+)*^ [13]
   Capillary BM thickening [12]  
(23 mo+)*^ [13]  
(28 mo+)^ [14]
• 24 mo+: dilated, hypercellular vessels*^ [13]
  IRMAs* [13]
• 28 mo+: disrupted retinal layers^ [14]
  Gliosis^ [14]
  Capillary dilatation^ [14]
  Microaneurysms (OPL, INL)^ [14]
   Increased number of endothelial 
cells^ [14]
*50% galactose diet; ^30% galactose diet
BB rat 1 60–120 days 
(90% hyper-
glycemic by 
90–120 days) 
[15]
•  6 mo: increased retinal capillary BM thickness 
[15, 18]
•  7.7 ± 1.1 mo: reduced and deranged basal 
infoldings of the RPE basal plasmalemma [16]
•  8 mo+: decreased pericyte/endothelial cell 
ratio [17]
  Decreased number of pericytes [17]
   Microinfarctions with nonperfused 
areas [19]
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Rat model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in rat models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or induction of VEGF overexpression)
NPDR features PDR features Functional changes (ERG)
WBN/ 
Kob rat
2 9–12 months of 
age [20]
•  5 mo: decreased outer segment 
thickness [21]
•  10 mo: clustering of capillaries into 
tortuous knots [22]
•  11 mo: decreased OPL and ONL 
thickness [21]
• 14 mo: capillary BM thickening [21]
   Complete photoreceptor cell nuclei and 
ONL loss ([21, 22], 169)
• 15 mo: decreased number of capillaries [22]
  Capillary loop formation [22]
• 19 mo: acellular capillaries [24]
24 mo:
•  Intravitreal and choroidal 
neovascularization [23, 24]
•  Increased hyalinization of 
intraretinal vessels [23]
•  Increased intravitreal proliferation 
of fibrovascular elements [23]
ZDF rat 2 6–7 wks of age 
[25]
•  14 wks: increased VEGF-beta mRNA levels 
in retina [26]
•  27 wks: capillary BM thickening [28]  
(6–7 mo) [27]
   Increased capillary hypercellularity [28] 
(6–7 mo) [27]
•  33–34 wks: increased pericyte apoptosis and 
presence of pericyte ghosts [29]
  Increased endothelial cell apopotosis [29]
   Increased number of acellular 
capillaries [29]
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Rat model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in rat models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or induction of VEGF overexpression)
NPDR features PDR features Functional changes (ERG)
OLEFT 2 18 wks of age 
[30]
• 24 wks: increased leukocyte entrapment [38]
•  28 wks: reduced total retinal and RNFL 
thickness [32]
• 36 wks: reduced number of RGCs [32]
  Increased apoptosis in RNFL [32]
•  40 wks: increased GFAP immunoreactivity 
in Müller cells [33]
• 14 mo: capillary BM thickening [31, 34]
  Endothelial cell degeneration [31, 34]
   Reduced pericyte area to total capillary 
cross-sectional area ratio [34]
  Caliber irregularity [34] (64 wks) [35]
   Capillary tortuosity [34] (64 wks) [35]  
(17 mo) [31]
   Capillary loop formation [34] (64 wks) [35] 
(17 mo) [31]
• 64 wks: capillary narrowing [35]
  Microaneurysms [35] (17 mo) [31]
•  19 mo: decreased INL and photoreceptor 
thickness [31]
  Decreased RPE height [31]
  Poorly developed basal infoldings [31]
60 wks:
•  Prolonged peak latencies of 
OPs [36]
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Rat model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in rat models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or induction of VEGF overexpression)
NPDR features PDR features Functional changes (ERG)
GK rat 2 (non-
obese)
4–6 wks of age 
[37] (glucose 
in-tolerance 
as early as at 2 
wks of age)
• 1 mo+: increased retinal mean circulation 
time [38]
• 3 mo+: increased BRB permeability [39]
• 28 wks: increased ocular VEGF 
concentrations [41]
• 8 mo: Increased endothelial/pericyte ratio [40]
• 12 mo+: Activated microglia [42]
1 mo (post hyperglycemia)
• 1 mo+: reduced retinal segmental 
blood flow [38]
• 12 mo: migration and 
accumulation of microglia/
macrophages in the subretinal 
space [42]
SDT 2 (non-
obese)
25 wks of age 
(male rats) 
(100% diabetic 
by 40 wks of 
age) [44]
• 40 wks: increased cellular apoptosis in GCL 
and INL [45]
  Increased GFAP immunoreactivity 
expression across the whole retina [45]
• 44 wks: increased retinal leukostasis [46]
• 52–60 wks: increased INL, ONL, PL, 
choroidal and total retinal thickness [47]
• 68 wks: fluorescein leakage around the optic 
disc [48]
  Venous dilation [48]
  Distorted retina [48] (70 wks) [44]
  Protrusion of optic disc into the vitreous
• 70 wks: retinal thickening [44]
• 77 wks: anterior chamber hemorrhage with 
fibrovascular changes around the iris [44, 49]
• 49–82 wks: acellular capillaries [49]
  Pericyte loss [49]
  Tortuous vessels [49]
  Capillary nonperfusion [49]
• 20 mo: increased VEGF immunoreactivity 
in vascular endothelial cells, GCL, INL, 
border between ONL and OS [50]
• 70 wks: tractional retinal 
detachment with fibrous 
proliferation [44, 49]
• 20 mo: neovascularization (53%) 
without ischemia [50]
• Tractional changes without retinal 
detachment [50]
32 weeks
• Prolonged OP peak 
latencies [48]
44 weeks
• Reduced a-, b-wave and OP1, 
OP2, OP3 amplitudes [51]
• Increased OP2, OP3, OP4 
implicit time [51]
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Rat model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in rat models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or induction of VEGF overexpression)
NPDR features PDR features Functional changes (ERG)
TetO rat 
[52]
2 7–8 days after 
incorporation 
of doxy-cycline 
in drinking 
water
4–5 weeks+ [52]
• RGC loss
• Reduced number of pericytes
• Increased number of stenotic vessels
• Increased number of veins with abnormal 
vessel caliber (deep microvascular plexus)
• BRB breakdown
• Increased GFAP expression
• Reactive gliosis
• Increased inflammatory markers
P18
• Intravitreal neovascularization in 
peripheral retina [54, 58]
ERG Changes 4–5 weeks after 
hyperglycemia onset
• Reduced a-waves, b-waves, and 
c-wave amplitude
• Elevated b/a-wave ratio
OIR / / • P13: perivascular astrocyte loss [54]
• P14–16: increased vascular permeability 
(ceased at p18) [55]
• P18: reduced peripheral INL(and central), 
IPL and total retinal thickness [56]
 Increased Müller cell gliosis in peripheral 
retina [54, 56]
  Increased tortuosity of arterioles [57]
 Decreased vessel profiles in outer and inner 
plexuses in peripheral retina [54, 58]
 Altered pericyte-endothelial 
interactions [54]
 Shortened retinal outer segment length [97]
ERG changes at p18
• Reduced a-wave and b-wave 
amplitude [57]
This table has been modified from a review by Lai and Lo [19].
Table 1. Summary of the cellular, molecular, and morphological features displayed in rat models of DR.
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Model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in non-rodent models
(Age at which correlates are first reported unless otherwise specified)
(+Time posttreatment: diabetes, galactosemia, or induction  
of VEGF overexpression)
NPDR features PDR features Functional 
changes 
(ERG)
Dog Galactose-fed / / • 19 mo+: pericyte loss [62] (36 mo+: increased endothelial/pericyte ratio [63])
• 24 mo+: uneven distribution of endothelial cells [62]
  Acellular capillaries [98] (36 mo+ [63])
  Endothelial proliferation (in areas with pericyte loss) [62] (36 mo+ [63])
• 27 mo+: microaneurysm [62] (32–36 mo+ [64]) (36 mo+ [63])
• 33 mo+: dot and blot hemorrhages [62, 64]
  Capillary varicose enlargement [62]
  Areas of nonperfusion [99] (36 mo+ [65] (56 mo+ [62])
• 36–48 mo+: hemorrhage [62]
• 56 mo+: preretinal hemorrhage [62]
  IRMAs [62]
• 60 mo+: AV shunts [62]
  Arterial node formation [62]
  Gliosis [62]
•  60 mo+: 
neovascularization [65]
•  84 mo+: intravitreal 
retinal vascular growth 
[62]
Partial detachment of 
posterior vitreous [62]
STZ injection 
[60]
• 1–3 yrs.+: capillary BM thickening
• 4 yrs.+: pericyte loss
  Smooth muscle cell loss
• 7 yrs.+: microaneurysms
  Acellular capillaries
  IRMAs
Alloxan 
injection
• 5 yrs.+: microaneurysm [61]
  Pericyte ghosts [61]
  Increased endothelial/pericyte ratio [61]
  Increased acellular capillaries [61]
  BM thickening [61]
  Vascular leakage, increased permeability of retinal blood vessels [100]
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Model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in non-rodent models
(Age at which correlates are first reported unless otherwise specified)
(+Time posttreatment: diabetes, galactosemia, or induction  
of VEGF overexpression)
NPDR features PDR features Functional 
changes 
(ERG)
Cat Pancreatotomy 1 1–2 weeks post 
surgery
• 3–10 mo+: capillary BM thickening [70]
• 5 yrs.+: microaneurysm [69] (7.7–9.4 yrs.+ [71])
• 6.5 yrs.+: small intraretinal hemorrhages [69] (7.7–9.4 yrs.+ [71])
• 7.5 yrs.+: IRMAs [69]
  Capillary non-perfusion areas [69] (9.4 yrs.+ [71])
• 8.5 yrs.+: microvessel dilation and tortuosity
•  8.5 yrs.+: small foci of 
neovascularization
9.4 yrs.+: 
decreased 
b-wave 
(trend) [71]
Rabbit STZ injection 1 135 days+:
•  10% eyes: “Moderate vasculopathy with hard or soft exudates, 
widespread hemorrhages” [75]
•  40% eyes: “Serious vasculopathy with serious retinal and preretinal 
hemorrhages, vascular lesions, hemovitreous, venous thrombosis” [75]
•  135 days+: 50% of 
eyes: proliferative 
retinopathy [75]
Diet-induced 
[72]
2 12–24 weeks • 12 wks+: increased number of microaneurysms
VEGF implant / / • 7 days+: increased dilation and tortuosity of vessels [73]
• 14 days+: vascular leakage [73]
•  14 days+: 
neovascularization 
(decreased after 
21 days with almost 
complete regression by 
35 days) [73]
VEGF + bFGF
•  48 hrs+: grade + 1 
neovascularization [74]
•  4 days+: grade 4 
neovascularization [74]
•  2 wks+: total traction 
retinal detachment 
with significant 
hemorrhage [74]
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Model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in non-rodent models
(Age at which correlates are first reported unless otherwise specified)
(+Time posttreatment: diabetes, galactosemia, or induction  
of VEGF overexpression)
NPDR features PDR features Functional 
changes 
(ERG)
Swine STZ injection 1 1 wk [79] • 18 wks+: capillary BM thickening with rarefaction [79]
Alloxan 
injection
1 15–30 days 
[76]
• 90 days+: increased GFAP in Müller cells [76]
• 20 wks+: capillary BM thickening [77]
• 20 wks (age): pericyte loss [78]
  Reduced total number of BRB capillaries [78]
  Capillary collapse [78]
Zebra 
fish
Glucose-
induced
1 1–2 days [90] • Day 28: decreased IPL and INL [90]
Glucose-
induced 
(flk:EGFP 
transgenic 
zebrafish)
•  6 dpf (3 days of glucose tx): increased diameter of hyaloid-retinal 
vessels [89]
Hypoxia-
induced
/ / • 3 days+: increased capillary sprouts in arterioles and veins [91]
  Increased number of branch points [91]
  Reduced intercapillary distance [91]
3 days+: 
neovascularization 
(increased vascular area) 
(plateau at day 12) [91]
vhl mutants / / • 5.75 dpf: increased hyaloid and choroidal vascular networks [101]
• 6 dpf: vascular leakage
dpf = days post fertilization
7.5 dpf:
•  Severe macular edema 
[101]
• Retinal detachment [101]
•  Intraretinal 
neovascularization 
(predominantly in IPL) 
[101]
This table has been modified from a review by Lai and Lo [19].
Table 2. Summary of the cellular, molecular, and morphological features displayed in nonrodent models of DR.
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Model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in non-human primate models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or VEGF overexpression–induction)
NPDR features PDR features Functional changes 
(ERG)
Monkey STZ injection, 
spontaneous or 
pancreatectomy 
[81]
1 / Changes observed in diabetic monkeys with spontaneous or 
pharmacologically-induced hypertension
• 6–15 yrs.+: focal intraretinal capillary leakage spots
  Capillary dilatation
  Capillary dropout
  Cotton wool spots
  Microaneurysms
  Arteriolar dilatation and occlusion
  Atrophic retinopathy
Spontaneous, 
obese
2 / • 3–8 yrs.+: cotton wool spots [82]
  Capillary dropout [82]
  Microaneurysms Kim, #413}
  IRMAs [82]
  Nonperfused areas [82]
• 8 yrs.+: RGC loss [83]
  Decreased ONL, IS, OS thickness [83]
•  3–8 yrs.+: cystoid macular 
edema [82]
8 yrs.+:
•  Reduced OPs 
[83]
•  Reduced 
amplitudes in 
mfERG
•  Delayed a-wave 
[83]
Intra-vitreal 
VEGF injection
/ / • 2 days+: tortuous vessels [85]
  Vascular leakage [85]
• 3 days+: vessel dilatation [84]
• 18 days+: microaneurysms [84]
  Intraretinal hemorrhage [84]
  Venous beading [84]
• 30 days+: intraretinal hemorrhage and edema [84]
•  2 days+: grade 2 iris 
neovascularization [85]
•  8 days+: grade 3 iris 
neovascularization [85]
•  19 days+: neovascular 
glaucoma [85]
VEGF implant / / • 3 wks+: vascular leakage (BRB breakdown) [73]
• 2–3 wks+: dilation of retinal vessels [73]
Note: vascular changes peaked at 3 wks
•  1 wk.+: iris 
neovascularization 
(regressed between wks 
2–3)
Animal Models of Diabetic Retinopathy (Part 2)
http://dx.doi.org/10.5772/intechopen.70589
51
Model Type of 
diabetes
Hyperglycemia 
onset
Cellular, morphological, and vascular features of human DR displayed in non-human primate models
(Age at which correlates are first reported unless otherwise specified)
(+Time post treatment: diabetes, galactosemia, or VEGF overexpression–induction)
NPDR features PDR features Functional changes 
(ERG)
Marmoset Galactose-fed 
(30%) [86]
/ / • 2.5 yrs.+: microaneurysm
  Increased acellular capillaries
  Pericyte loss
  BM thickening
  BRB breakdown
•  Macular edema and 
thickening
This table has been modified from a review by Lai and Lo [19].
Table 3. Summary of the cellular, molecular, and morphological features displayed in nonhuman primate models of DR.
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1.1. Rat models
1.1.1. Pharmacological
1.1.1.1. Streptozotocin (STZ) injection
Streptozotocin (STZ) injection diabetic rats reproduce early symptoms of DR, though prom-
inent differences have been identified between rat strains possibly as a result of differing 
genetic susceptibility to DR development. A report comparing differences in the develop-
ment of DR lesions in Sprague Dawley, Lewis, and Wistar rats revealed that neuronal loss in 
the ganglion cell layer (GCL) occurred only in Lewis rats, while both Lewis and Wistar rats 
showed degeneration of capillaries with pericyte ghosts after 8 months of hyperglycemia [1]. 
Sprague Dawley rats did not develop any lesions.
In general, neuronal and glial changes appear to precede vascular changes in this model. Retinal 
apoptosis and retinal thinning developed within 1–2 weeks of hyperglycemia. Müller cell gliosis, 
as evidenced by increased glial fibrillary acidic protein (GFAP) expression, was prominent begin-
ning at 4 weeks of hyperglycemia [2–5]. Studies have also documented a reduction in astrocyte 
number and processes [2, 5], decrease in the number of cells in the GCL [1, 3], and an increase in 
number of microglia [1, 3] after 4–6 weeks of hyperglycemia. Blood-retina barrier (BRB) break-
down was present after 2 weeks of hyperglycemia, while other vascular changes, including acel-
lular capillaries [1, 6], leukostasis [7], and arterial and venous capillary basement membrane 
(BM) thickening [8], were only present after a longer period of hyperglycemia. Pericyte loss 
became evident after 4 [6] or 8 months [1] of hyperglycemia. Retinal dysfunction was evidenced 
by decreased b-wave [4, 6, 9] and OP amplitude [4, 6] and decreased a-wave amplitude [4, 9] with 
delayed oscillatory potentials (OP) [9] as early as at 2 weeks and 10 weeks, respectively.
1.1.1.2. Alloxan injection
Studies using alloxan injections for diabetes-induction are limited, and none have assessed 
for neurodegenerative lesions of DR. Alloxan-induced diabetic rats were found to have BRB 
breakdown within 6 weeks of hyperglycemia. With a longer duration of diabetes, there 
was retinal microvascular cell death [10], intraretinal microvascular abnormalities (IRMA) 
[11], pericyte ghosts [12], acellular capillaries [10, 12], and capillary BM thickening [12]. 
Neovascularization began in the mid-peripheral retina after 2 months of hyperglycemia 
and extended to all regions of the retina by 9 months [11].
1.1.2. Diet induced
Galactose-fed rats display many retinal microangiopathy features that resemble non-proliferative 
diabetic retinopathy (NPDR). Four months of 30% galactose-fed diet resulted in increased retinal 
microvascular cell apoptosis [10]. With a longer duration of galactosemia, pericyte ghosts, acellu-
lar capillaries, vessel dilation, capillary BM thickening, and IRMAs became evident in both 30 and 
50% galactose-fed rats [12–14]. Long-term galactosemia of 28 months further resulted in gliosis, 
displacement or disruption of retinal layers, an increase in the number of endothelial cells, and 
microaneurysm formation in the outer plexiform layer (OPL) and inner nuclear layer (INL) [14].
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1.1.3. Transgenic
1.1.3.1. Biobreeding (BB) rats
The diabetes-prone biobreeding (BB) rat is a T1D model derived from outbred Wistar rats. 
BB rats develop insulitis with selective β-cell destruction, hyperglycemia, hyperketonemia, 
ketonuria, and hypoinsulinemia. Rapid progression to fatal diabetic ketoacidosis results if 
exogenous insulin is not administered. The majority of rats develop hyperglycemia by the age 
of 90–120 days [15]. Existing reports have demonstrated reduced and deranged basal infold-
ings of the retinal pigment epithelium (RPE) basal plasmalemma [16], pericyte loss, reduced 
pericyte to endothelial cell ratios [17], capillary BM thickening [15, 18], and microinfarctions 
[19]. Microaneurysm formation and neovascularization were absent even after 11 months of 
diabetes [19]. Characterization studies of DR using this model remain limited. Subsequent 
inbreeding and outbreeding have produced various genetically distinct substrains (named 
after the origin of the colony), including the BBDP/Wor, BB/OK, and BB/Pfd rat. Care should 
be taken when comparing results of studies utilizing rats of different substrains due to poten-
tial genetic and phenotypic differences.
1.1.3.2. Wistar Bonn/Kobori (WBN/Kob) rats
The Wistar Bonn/Kobori (WBN/Kob) rat is a nonobese T2D strain of Wistar rats that develop 
exocrine pancreatic insufficiency characterized by α- and β-cell destruction. Male rats 
develop hyperglycemia at around 9–12 months of age, while females remain unaffected [20].
The retinal changes in this rat model have long been argued to be more degenerative than 
diabetic. At the age of 5 months, prior to the development of hyperglycemia, the rats showed 
signs of retinal degeneration with the loss of rods and cones and thinning of the photoreceptor 
layers [21]. Although retinal capillary changes, such as capillary BM thickening [21], reduced 
capillary number, formation of capillary loops, presence of acellular capillaries, and cluster-
ing of capillaries into tortuous knots [22], were observed after hyperglycemic development, it 
is uncertain whether these changes arose from the development of diabetes or resulted from 
further progression of retinal degeneration. WBN/Kob rats survive for a longer duration under 
diabetic conditions compared to other models. Perhaps, this prolonged survival and hypergly-
cemia duration had led to the development of intravitreal and choroidal neovascularization, 
which was accompanied by the hyalinization of intraretinal vessels and increased proliferation 
of fibrovascular elements in the vitreous at 24 months of age [23, 24]. Such features had not 
been previously reported in other rats. The proliferative changes were mostly absent in non-
diabetic age-matched female counterparts [23], suggesting that the WBN/Kob rat may serve 
as a diabetic angiopathy model. Nevertheless, the retinal degenerative changes in the WBN/
Kob rats are arguably different from that of human DR, making it a less suitable model for DR.
1.1.3.3. Zucker diabetic fatty (ZDF) rats
The Zucker diabetic fatty rat (ZDF/Gmi, fa/fa) is a T2D model derived from the partial inbreeding 
of the fa/fa line. The rats carry an inherited mutation in the leptin receptor and need to be main-
tained on a specialized diet to ensure consistent diabetes development. Male rats display marked 
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hyperglycemia, hyperinsulinemia, insulin resistance, and obesity at 6–7 weeks of age [25]. Studies 
have reported increased vascular endothelial growth factor (VEGF) expression in the retina that 
correlated with retinal levels of inflammatory markers at 14 weeks of age [26], capillary BM thick-
ening with increased retinal capillary hypercellularity at 27 weeks [27, 28], and increased pericyte 
apoptosis, endothelial apoptosis, presence of pericyte ghosts and number of acellular capillaries 
as compared to the lean controls by 33–34 weeks [29]. The rats have a relatively short lifespan of 
1 year but do not require insulin treatment while exhibiting consistently marked hyperglycemia 
with glucose levels averaging at 500 mg/dL when fed with the appropriate diet. To date, few reti-
nal morphological and therapeutic drug studies have been performed on this rat model.
1.1.3.4. Otsuka Long-Evans Tokushima fatty (OLETF) rats
The Otsuka Long-Evans Tokushima fatty (OLETF) rat is a T2D model originally generated from 
selective breeding of the Long-Evans rats that spontaneously exhibited polyuria, polydipsia, 
and obesity. The OLETF rat is characterized by mild obesity, a late onset of chronic hypergly-
cemia after the age of 18 weeks, male inheritance, pancreatic islet hyperplasia, and the develop-
ment of T2D as a result of metabolic syndrome [30]. Significant weight gain occurs between the 
age of 1 and 6 months followed by significant weight loss after the age of 9 months [31].
The rats display an array of retinal cellular morphological changes corresponding to the early 
stage of DR. Increased leukocyte entrapment was first reported in 24-week-old rats. Spectral 
domain optical coherence tomography (SD-OCT) revealed significant thinning of the total ret-
inal and retinal nerve fiber layer (RNFL) at the age of 28 weeks [32]. There was retinal ganglion 
cells (RGC) loss with nonuniform distribution of remaining RGCs and increased apoptosis in 
the RNFL at 36 weeks [32]. GFAP and VEGF immunoreactivity were upregulated, with VEGF 
expression extending across all layers of the retina into the OPL [33]. By 14 months of age, 
there were endothelial cell degeneration, capillary BM thickening, and pericyte loss [31, 34]. 
A longer duration of hyperglycemia resulted in the reduction in INL thickness, photoreceptor 
thickness, and RPE height with poorly developed basal infoldings, suggestive of neurodegen-
eration. Rats aged 14–17 months have consistently exhibited marked microvascular changes, 
including vessel tortuosity, caliber irregularity, capillary loop formation, capillary narrow-
ing, and microaneurysms [31, 34, 35]. One study further revealed prolonged peak latencies 
of OPs on ERG, particularly OP1 and OP3, [36], although experimental conditions may have 
accounted for such abnormalities.
Existing characterization studies have only been performed by a selective number of research 
groups. Despite the similarities in the pathophysiology of T2D in OLETF rats and humans, 
the use of OLETF rats in DR studies is limited by the model’s late onset of hyperglycemia and 
absence of late-stage DR features. The presence of hemorrhages, exudates, and acellular capil-
laries has not been reported in rats up to 19 months of age [31], signifying its unsuitability as 
an angiopathic DR model.
1.1.3.5. Nonobese Goto-Kakizaki (GK) rats
The GK rat is a nonobese T2D model that develops glucose intolerance at 2 weeks of age and 
significant hyperglycemia by the age of 4–6 weeks [37]. The rats were generated from repeated 
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selective inbreeding of normal Wistar rats based on their glucose intolerance indices [37]. After 1 
month of hyperglycemia, the rats displayed significantly increased retinal mean circulatory time 
and reduced retinal segmental blood flow [38]. BRB permeability was increased after 3 months 
of hyperglycemia [39]. Eight-month-old rats presented with an increased endothelial/pericyte 
ratio that increased with the duration of hyperglycemia [40]. At 28 weeks, there were increased 
ocular VEGF concentrations, with significant immunoreactivity in the choroid [41]. This corre-
sponds to the VEGF localization in the eyes of diabetic patients [41]. With 12 months of chronic 
hyperglycemia, microglia were activated and migrated into the subretinal space between the 
outer segment and RPE [42], as seen in human proliferative diabetic retinopathy (PDR) with 
diabetic maculopathy [43]. These retinal microcirculatory changes, however, were not accom-
panied with retinal vessel diameter or morphological changes. The stable diabetic state of this 
model allows for the investigation of retinal changes over an extended duration of diabetes.
1.1.3.6. Spontaneously diabetic Torii (SDT) rats
The spontaneously diabetic Torii (SDT) rat is a type 2 diabetic inbred strain of the Sprague-
Dawley rat generated by selective breeding of SD rats with polyuria and glucosuria. The rats 
display glucosuria, hypoinsulinemia, and hyperglycemia without signs of ketonuria. There 
are prominent sex differences in diabetes development in these rats. Female and male rats 
develop hyperglycemia by 10 and 20 weeks, respectively, but 100% cumulative incidence of 
diabetes was only observed in male 40-week-old rats [44]. Merely, 33.3% of female rats devel-
oped diabetes by 65 weeks of age [44].
The SDT rat is one of the few rodent models that display advanced lesions and features 
resembling PDR with prolonged hyperglycemia. Increased cellular apoptosis in the GCL and 
INL and increased GFAP expression spanning the entire retina [45] were evident at the age of 
40 weeks. There was increased retinal leukostasis [46] and retinal thickening [47] by the age of 
44 and 52–60 weeks, respectively. Long-standing hyperglycemia in rats older than 60 weeks 
of age has been shown to result in the distortion of the retina, fluorescein leakage around the 
optic disc, vessel tortuosity, capillary nonperfusion, neovascularization, and tractional retinal 
detachment accompanied by proliferative fibrous formations [48] (70 weeks) [44, 49]. Anterior 
chamber hemorrhage with fibrous proliferation around the iris and posterior synechia forma-
tion were also noted in a few cases [44, 49]. A major discrepancy between the rat model and 
human DR is the development of retinal neovascularization and proliferative DR features in 
the SDT rat in the absence of retinal ischemia [50]. The presence of microaneurysms and areas 
of vascular nonperfusion were also rarely reported in this model. Retinal dysfunction was 
evidenced by delayed OP peak latencies at 32 weeks of age [48] and reduced a-wave, b-wave, 
and OP amplitudes with increased OP implicit times at the age of 44 weeks [51].
The SDT rat has a relatively long lifespan without requiring exogenous insulin administra-
tion. Hence, it may serve as a unique rodent model for PDR, considering that the SDT rate 
retinae can be exposed to high concentrations of VEGF for a longer period of time. Some 
researchers have further introduced the fa mutation of the leptin receptor gene found in ZF 
rats into the SDT rat to create a SDT fatty rat that develops diabetes and diabetes-associated 
complications at a younger age.
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1.1.3.7. TetO rat
The NTac:SD-Tg(H1/tetO-RNAi:Insr) (TetO) transgenic rat is a newly reported rat model of 
T2D exhibiting both hyperglycemia and hyperinsulinemia [52]. The insulin receptor (INSR) 
gene is reversibly knocked down through the use of tetracycline-inducible small hairpin RNA 
(shRNA) expression systems [53]. INSR expression is inhibited upon doxycycline adminis-
tration in drinking water, resulting in insulin resistance. After 4–5 weeks of hyperglycemia, 
RGC and pericyte loss were observed. The rats displayed an increase in the number of ste-
notic vessels and veins with abnormal caliber. Blood-retina barrier (BRB) disruption was evi-
denced by albumin extravasation and reduced zonula occludens-1 expression in the RPE. 
Increased expression of GFAP and inflammatory markers was also observed in the rat retinae. 
Functionally, ERG studies revealed significantly decreased scotopic a-waves, b-waves, and 
c-waves, and an elevated b/a-wave ratio.
The reversible nature of the tetracycline-inducible shRNA system allows for fine modulation of 
the degree of hyperglycemia to be induced in the rats. This may be useful for the reproduction 
of clinical situations in an animal model. The rats also project an array of early and late features 
of human DR within a shorter time span as compared with other rodent models of DR. Given 
that only one study to date has documented retinopathy changes in the TetO rat, no detailed 
reports of the timeframe of pathophysiological changes in the retinae are currently available.
1.1.4. Angiogenesis
1.1.4.1. Oxygen-induced Retinopathy (OIR)
In Sprague-Dawley rats, the OIR model predominantly induced vascular changes in the 
peripheral retina. Two days after pups were transferred to normoxia, there was evident peri-
vascular astrocyte loss [54]. This was followed by significantly increased vascular permeability 
until P18 [55]. At P18, there was significant reduction in INL, inner plexiform layer (IPL), and 
total retinal thickness [56] and increased arteriole tortuosity [57]. Increased Müller cell gliosis, 
as demonstrated by increased GFAP immunoreactivity, was particularly prominent in avas-
cular areas of the retina [56]. Although pericyte apoptosis, a prominent feature of DR, was not 
observed, pericyte-endothelial interactions were abnormal [54]. This may likewise compromise 
vascular wall stability. Intravitreal neovascularization was accompanied with decreased blood 
vessel profiles in the outer and inner plexuses and abnormal vessel tufts extending from the 
superficial plexus in an extraretinal direction [54, 58]. Functionally, a- and b-wave amplitudes 
on ERG were reduced in OIR rats [55]. It has been suggested that the degree of vascular hyper-
permeability, development of vascular pathologies, and area of avascularity differs, according 
to the strain of mice used and the degree of VEGF overexpression [55, 59]. Researchers should 
be meticulous in their selection of rat strains to ensure that desired phenotypes are displayed.
1.2. Nonrodent models
Nonrodent models, including dogs, cats, rabbits, pigs, and zebrafish, have been used for DR 
studies. Larger animals have eyes that are more similar to human eyes in terms of size and 
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structure. Larger eyes also allow for the extraction of retinal cells and components of the vit-
reous for further in vitro studies. Nonhuman primates are ultimately most similar to humans 
anatomically, particularly in regard to the presence of the macula. However, significant costs, 
ethical challenges, genetic intractability, and feasibility issues regarding the housing and han-
dling of such large animals greatly limit their use. Further studies are required for the estab-
lishment of reported features in the following nonrodent models due to the small sample 
sizes and large intra-species variations in existing reports.
1.2.1. Dog models
Diabetes has been induced in dogs via STZ injections or galactose feeding. Both diabetic and 
galactose-fed galactosemic dogs display retinal lesions similar to those of human DR, though 
a long duration of galactose feeding is required for the development of vessel changes asso-
ciated with PDR. Diabetic dogs displayed capillary BM thickening within 1 year of hyper-
glycemia, pericyte and smooth muscle cell loss at 4 years, and microaneurysms, acellular 
capillaries, and IRMAs after 7 years of diabetes [60]. Similar lesions were found in alloxan-
induced diabetic dogs after 5 years of diabetes, though such changes were significantly more 
evident in galactosemic dogs [61]. Galactosemic dogs have been reported to develop features 
of both NPDR and PDR [62–65], including intravitreal retinal vascular growth and partial 
detachment of the posterior vitreous after 84 months of 30% galactose feeding [62]. Some have 
suggested that pericyte destruction and microaneurysm formation are age dependent, with 
younger animals developing such symptoms at a faster rate than older animals [63].
1.2.2. Cat models
The cat eye has a retinal and choroidal circulation comparable to that of the human eye [66]. 
The feline lens advantageously does not develop diabetic cataracts, thus allowing for clear 
visualization of the fundus [67]. The majority of studies of diabetic cats involve induction 
of diabetes via pancreatectomy. Among the few studies published, there are discrepancies 
regarding the presence of reported lesions. Within the small sample size, some observed 
microaneurysms, capillary BM thickening, increased vessel tortuosity, decreased b-waves, 
capillary nonperfusion, and small intraretinal hemorrhages [68–71], while other cats did not 
develop microaneurysms or hemorrhage [68]. It is worth noting that the inner half of the dia-
betic retinae becomes hypoxic prior to the development of apparent capillary nonperfusion. 
This may be comparable with hypoxia-stimulated VEGF expression in humans prior to the 
development of DR [67]. The use of cats for DR studies is less feasible due to the slow develop-
ment of lesions and high costs.
1.2.3. Rabbit models
Although the rabbit globe is significantly larger than that of rodents, rabbits possess a meran-
giotic retinal circulation, where the inner retina is supplied by choriocapillaris [66]. Humans, 
rodents, dogs, cats, pigs, and primates have a dual holangiotic circulation, where the inner 
retina is supplied by central and cilioretinal arteries, and the outer retina is supplied by the 
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choriocapillaris. Pharmacological, diet-induced hyperglycemia and hypercholesterolemia 
(lard, sucrose, and cholesterol-added chow [72]), and VEGF injection models (implantation 
of a human recombinant VEGF pellet into the vitreous [73, 74]) have been used in rabbits 
for DR studies. However, the presence of DR lesions is highly variable between and within 
models. Rabbits with STZ-induced diabetes demonstrated varying degrees of retinopathy 
after 135 days of hyperglycemia. Some showed proliferative retinopathy, while others only 
demonstrated moderate vasculopathy with hemorrhages and hard or soft exudates [75]. Diet-
induced hyperglycemic and hypercholesterolemic rabbits only exhibited an increased num-
ber of microaneurysms after 12–24 weeks of special feeding. The development of vascular 
pathologies and neovascularization in the VEGF implant model was limited by the gradual 
depletion of VEGF [73]. Neovascularization developed 14 days after the implant was inserted, 
but there was almost complete regression by 35 days. The addition of basic fibroblast growth 
factor (bFGF) to the pellet in another study demonstrated a faster induction of retinopatholo-
gies [74], but angiogenic responses may vary depending on the strain of rabbits used.
1.2.4. Porcine models
The retinal structure of the pig eye, with its holangiotic retinal circulation and area centralis 
comparable to the human macula, closely resembles that of the human eye [66]. Few studies 
have examined morphological changes in the pig retinae. Alloxan-induced pigs developed 
Müller cell gliosis at 90 days of hyperglycemia [76]. By 20 weeks, pigs developed capillary BM 
thickening [77], pericyte loss, and capillary collapse with a reduction in the total number of 
BRB capillaries [78]. STZ-induced pigs showed similar results, with capillary BM thickening 
and lamellation and rarefaction on electron microscopy at 20-week post-STZ treatment [79]. 
A proliferative vitreoretinopathy swine model has also been developed, whereby vitreal and 
retinal detachments were induced surgically prior to the intravitreal injection of RPE cells 
[80]. However, it is not a suitable angiogenesis model for DR.
1.2.5. Nonhuman primates
1.2.5.1. Monkey models
Monkeys are the most common primate models used for DR studies. Investigations in 39 STZ-
induced, pancreatectomy-induced, or spontaneously hyperglycemic T1D monkeys revealed 
only mild ocular changes after 6–15 years of diabetes [81]. There were no signs of PDR. Only 
diabetic monkeys that spontaneously developed hypertension or those that were pharmaco-
logically induced to develop hypertension displayed ischemic retinopathy changes, including 
microaneurysms, capillary dilatation and dropout, focal intraretinal capillary leakage spots, 
cotton wool spots, and arteriolar lesions. Spontaneously obese type 2 diabetic monkeys devel-
oped various retinal lesions and displayed signs of retinal functional loss on ERG, but lesion 
development was highly variable among individual monkeys [82, 83]. Occurrence of retinop-
athy was significantly correlated with the presence of hypertension, as seen in the type 1 dia-
betic monkey models. Angiogenesis monkey models have also been reported, where repeated 
intravitreal VEGF injections resulted in vessel tortuosity, dilation, leakage, microaneurysm 
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formation, venous beading, capillary nonperfusion, and preretinal neovascularization [84]. 
Both VEGF injections and implants resulted in iris neovascularization [73, 85]. Despite their 
anatomical similarities to human eyes, DR development is highly variable and exceedingly 
slow, making it an impractical model for DR studies.
1.2.5.2. Marmoset models
An alternate primate model is the marmoset. The marmoset has large eyeballs in respect to its 
body size with anatomical features closely resembling those of the human eye. The only study 
to date characterizing the development of retinal DR lesions in these animals reported the 
development of microaneurysms with increased acellular capillaries, pericyte loss, BM thick-
ening, BRB breakdown, and macular edema in marmosets that were put on a 30% galactose-
rich diet for two and a half years [86].
1.2.6. Zebrafish models
Zebrafish (Danio rerio) uniquely offers the tractable genetics of rodent models and a retinal 
structure resembling that of the human eye. They have the distinctive five-layered human 
retinal structure, though they lack the subretinal plexi found in the inner and outer retina 
of human retinae [87, 88]. Despite lacking a macula, the density and number of cones in the 
zebrafish are comparable to that of humans.
Researchers have developed high-glucose diabetic and angiogenic models to mimic DR. 
Hyperglycemia was induced by immersing zebrafish into glucose-added water [89, 90]. This 
resulted in reduced IPL and INL thickness [90] and increased diameter of hyaloid retinal ves-
sels [33]. Zebrafish subjected to a hypoxia-induced retinopathy model developed neovascular 
features after 3 days [91]. One group developed an angiogenesis model using vhl (von Hippel-
Lindau tumor suppressor gene) mutant fish. By inactivating the vhl tumor suppressor gene, 
hypoxia-inducible factor was upregulated, resulting in overproduction of VEGF. Extensive 
neovascularization and PDR features were observed in these vhl mutant zebrafish, but such a 
model is not commercially available.
The short lifespan, rapid development, and capability of zebrafish to breed in exceedingly large 
numbers allow for high-throughput screening [88], genetic screening, and significantly shorter 
experimental turnover times as compared with that of rodents. Techniques for developing trans-
genic lines and gene-targeting mutations have also been established. Although the presence of 
DR-like lesions and exact models ideal for the simulation of DR have not yet been well estab-
lished, the zebrafish represents a promising short-term model for future DR drug screening.
2. Next-generation DR models and conclusion
The ideal animal model for DR would mimic the complete pathophysiological process of DR 
in humans, with initial development of NPDR features and gradual progression to PDR with 
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or without macular edema in the presence of prolonged hyperglycemia. However, the major-
ity of existing animal models only display early or advanced lesions of DR. DR has a complex 
etiology, with various genetic and environmental factors implicated in its disease suscepti-
bility and progression. Animal models are particularly important for the screening of novel 
therapeutic interventions. The clinical application of gene therapy for DR has been garnering 
increasing interest, and this may call for animal models that better reflect the intricacies of DR 
pathogenesis. Mice and rats are highly genetically tractable, but current transgenic models 
are based on isolated crosses [92]. Increasing development and use of resources such as The 
Collaborative Cross [92] may be required to enhance future identification and development 
of mouse strains with complex traits and epigenetics that are more reflective of the clinical 
scenario. Only by identifying and manipulating genes that mediate clinically relevant pheno-
types can we realize and exploit the full genetic tractability of the mouse to better model DR.
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